ChromaDex (CDXC)
(Delayed Data from NSDQ)
$2.98 USD
-0.22 (-6.88%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $2.97 -0.01 (-0.34%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth C Momentum B VGM
Brokerage Reports
ChromaDex Corporation [CDXC]
Reports for Purchase
Showing records 1 - 20 ( 113 total )
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Solid 1Q Results and Guidance Show Company On Solid Path to Profitability.
Provider: Roth Capital Partners, Inc.
Analyst: MCGOWAN S
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Top-Line In-Line, Modest Bottom-Line Beat; 1Q24 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
1Q24 Preview - Expecting A Good Start to 2024
Provider: Roth Capital Partners, Inc.
Analyst: MCGOWAN S
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Recent Transactions Suggest Significant Hidden Value; Raising Price Target
Provider: Roth Capital Partners, Inc.
Analyst: MCGOWAN S
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Top- and Bottom-Line Beat; 2023 Financials; Raising PT to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Black Ink! Company Posts 1st Profitable Quarter Since Launch of Tru Niagen
Provider: Roth Capital Partners, Inc.
Analyst: MCGOWAN S
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Solid 3Q Results, Cautious 4Q Guidance Points to Strong Growth in 2024
Provider: Roth Capital Partners, Inc.
Analyst: MCGOWAN S
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Top-Line Miss, Bottom-Line Beat; 3Q23 Financials; Reiterating Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Revenue In Line, Bottom-Line Beat; 2Q23 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Solid 2Q: Positive Cash Flow Driven By Modest "Beats" On Most Metrics
Provider: Roth Capital Partners, Inc.
Analyst: MCGOWAN S
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Q1 Stronger Than Expected; With Good Revenue Momentum and Cost Discipline
Provider: Roth Capital Partners, Inc.
Analyst: MCGOWAN S
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Record Quarterly Revenue; Lukewarm Outlook; Adjusting PT to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Q4 Sales, Op. Inc. in Line; Posts First Positive Adj. Quarterly EBITDA
Provider: Roth Capital Partners, Inc.
Analyst: MCGOWAN S